Bausch Health Companies (DB:BVF) - Prezzo delle azioni, notizie e analisi

BVF Panoramica delle azioni

Bausch Health Companies Inc. opera come azienda diversificata di specialità farmaceutiche e dispositivi medici negli Stati Uniti e a livello internazionale. Maggiori dettagli

BVF analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	3/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Negoziato a 84.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 218.28% all'anno

Gli utili sono cresciuti del 34.6% all'anno negli ultimi 5 anni

Analisi del rischio

Patrimonio netto negativo

Bausch Health Companies Inc. Concorrenti

Dermapharm Holding

XTRA:DMP

€2.0b

Bayer

XTRA:BAYN

€18.8b

PharmaSGP Holding

XTRA:PSG

€304.6m

Merck KGaA

XTRA:MRK

€61.7b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bausch Health Companies
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$8.66
Massimo di 52 settimane	US$9.82
Minimo di 52 settimane	US$4.69
Beta	0.74
1Variazione di 1 mese	17.12%
Variazione a 3 mesi	68.01%
Variazione di 1 anno	n/a
3Variazione a 3 anni	-58.46%
Variazione a 5 anni	-66.49%
Variazione dall'IPO	-4.21%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	BVF	DE Pharmaceuticals	DE Mercato
7D	0%	1.6%	1.1%
1Y	n/a	-19.0%	7.2%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato BVF rispetto al settore German Pharmaceuticals.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di BVF rispetto al mercato German.

Volatilità dei prezzi

Is BVF's price volatile compared to industry and market?
BVF volatility
BVF Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: I dati non sono disponibili.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di BVF nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. opera come azienda diversificata di specialità farmaceutiche e dispositivi medici negli Stati Uniti e a livello internazionale. Sviluppa, produce e commercializza una serie di prodotti principalmente in gastroenterologia, epatologia, neurologia, dermatologia, prodotti farmaceutici internazionali, prodotti da banco (OTC), dispositivi medici estetici e salute degli occhi. L'azienda opera attraverso cinque segmenti: Salix, International, Solta Medical, Diversified e Bausch + Lomb.

Bausch Health Companies Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bausch Health Companies con la sua capitalizzazione di mercato?
BVF statistiche fondamentali
Capitalizzazione di mercato	€2.83b
Guadagni(TTM)	-€168.48m
Ricavi(TTM)	€8.97b

0.3x

Rapporto P/S

-16.8x

Rapporto P/E

BVF è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BVF Conto economico (TTM)
Ricavi	US$9.47b
Costo del fatturato	US$2.76b
Profitto lordo	US$6.71b
Altre spese	US$6.89b
Guadagni	-US$178.00m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.48
Margine lordo	70.87%
Margine di profitto netto	-1.88%
Rapporto debito/patrimonio netto	-8,887.2%

Come si è comportato BVF nel lungo periodo?

Vedi performance storica e confronto

BVF Panoramica delle azioni

Premi

Analisi del rischio

Bausch Health Companies Inc. Concorrenti

XTRA:DMP

€2.0b

XTRA:BAYN

€18.8b

XTRA:PSG

€304.6m

XTRA:MRK

€61.7b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings released: EPS: US$0.027 (vs US$0.071 in 2Q 2023)

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023)

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

No longer forecast to breakeven

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold €708k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Investor sentiment improved over the past week

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit